



Drug Name: Taurolidine 1.35% and 4% citrate (Taurolock®)

NIM Number: 2020-151 v2

# Nurse Initiated Medication

Medications should be administered according to this protocol by hospital-accredited staff only. The protocol includes sufficient detail on the medication for the direction and information of nursing staff.

**This is a new protocol.**

**No preparation containing Schedule 4 or Schedule 8 drugs may be included in this Nurse Initiated Protocols**

Nurse initiated medications are not be administered on an **ongoing** basis without a medical review. If, on review, the medication is to continue, it must be ordered on the medication chart by the medical officer.

**Drug Name: Taurolidine 1.35% and 4% citrate (Taurolock®)**

**Valid until: 31 Aug 2026**

**Approved by Medicine and Therapeutics Committee on: 7/08/23**

**Developed by:**

**Team Leader:** Sarah Wallace

**Department:** CVAD Working Party

**Team Members:**

1. Sarah Wallace
2. John Watt
3. Brad Rockcliff
4. Tony Lai

**Description of the drug:**

- Citrate is an anticoagulant. It works as a calcium binder affecting coagulation cascade.
- Cyclo-taurolidine is an antimicrobial. It works by an amino acid derivative which interacts with bacterial cell wall causing irreparable injury.

**Expected outcomes:**

- Maintain CVAD patency by reducing CVAD-related infection and occlusion

**Side effects:**

- No known adverse effects
- May cause mild hypocalcaemic symptoms if given systemically

**Dosage range:**

- 1-3 mL of Taurolock (volume dependent on device type)

**Strength (where applicable):**

- Taurolidine 1.35% and citrate 4%

**Route of administration:**

- Intraluminal

**Indications/patient eligibility criteria:**

- Patients receiving administration of taurolock for this indication must have a Central Venous Access Device (CVAD)
- Maximum once daily administration per lumen as per CVAD policy (some devices may have up to 3 lumens)

Drug Name: Taurolidine 1.35% and 4% citrate (Taurolock®)

NIM Number: 2020-151 v2

### Contraindications (including possible interaction with other drug therapy):

- Patients with a known allergy to citrate or cyclo-taurolidine or when a patient is currently taking medication with known adverse interaction to citrate or cyclo-taurolidine

### Restrictions on categories of staff who may administer the medication and/nursing accreditation criteria , including completion of current nursing education package where applicable:

- **Registered** nurses employed by SCHN
- New **Graduate** nurses after first 6 months
- Can only be administered by staff who have completed the CVAD Clinical Skills Assessment Accreditation, including RN, CNS, CNC, CNE, NUM, NP. Second checker can be any medication endorsed nursing or medical staff.

### Any other information deemed necessary:

- Nil.

### Process for documentation:

- **Documentation** must be completed in eMR. Paper documentation must be used for areas without eMR/eMM and during downtime.

### Nursing assessment: (all documentation to be kept in clinical area by CNE or NE)

- Nursing **assessment** includes
  - a. Completion of the SCHN CVAD Core Skills Clinical Skills Assessment (CSA)
  - b. Completion of the eMR Quickstart – *Ordering a Nurse Initiated CVAD Lock Solution* (available via learning.kids <https://learning.schn.health.nsw.gov.au/ordering-nurse-initiated-cvad-lock-solution>). Acknowledgement of completion to be recorded on the SCHN CVAD Core Skills Clinical Skills Assessment (CSA).

### Observations

- Catheter related blood stream infections (CRBSI)
- CVAD occlusion
- Standard nursing and CVAD observations

### Expectation of the RN initiating the medication is to:

1. **Notify** a Medical Officer of the administration as soon as practical
2. **Clearly** document and sign on eMM the date/time and dose given. PNIMC (Paper medication chart) for any areas using/in downtime.
3. **Document** within Health-E-Care system for ED patients only

### Time/dose limit that a RN can initiate a Nurse Initiated Medication before consultation with a medical officer

- Further doses can be administered PRN once within 24 hours.

### References

- TauroPharm GmbH. Taurolock™ Antimicrobial Catheter Lock System To Provide Patency and Infection Control [brochure]. Germany. Manufacturer TauroPharm GmbH
- Taurolock [package insert]. Australia. TauroPharm GmbH, Jagerstrasse 5a, D-97297 Waldbüttelbrunn, Germany; 2016
- The Sydney Children's Hospitals Network. (2020). Central Venous Access Devices (CVAD) Practice Guideline. Doc. no. 2013-9037. Retrieved from <http://webapps.schn.health.nsw.gov.au/epolicy/policy/5119/download>